Cardiac Events after Allo-HCT in Patients with Acute Myeloid Leukemia. Study Conducted con Behalf of the GETH-TC

This multicenter study sponsored by GETH-TC aimed to investigate the incidence and predictors of early (within the first 100 days) and late cardiac events (CE) (ECE and LCE) following allo-HCT in AML patients treated with anthracyclines, focusing on exploring the impact of PTCY on cardiac complicati...

Descripción completa

Detalles Bibliográficos
Autores: Salas, M Queralt, Cascos, Enric, Lopez-Garcia, Alberto, Pérez López, Estefanía, Baile-González, Mónica, Martín-Rodriguez, Carlos, Pascual-Cascón, María Jesús, Luque Garrido, Marta, Esquirol, Albert, Heras, Inmaculada, Peña-Muñóz, Felipe, Oiartzabal Ormategi, Itziar, Sáez-Marín, Adolfo Jesús, Fernández-Luis, Sara, Dominguez-Garcia, Juan Jose, Villar, Sara, Fernández de Sanmamed Girón, Miguel, González-Pinedo, Leslie, Garcia-Maño, Lucia, Gonzalez-Rodriguez, Ana Pilar, Torrado Chedas, Tamara, Filafferro, Silvia, Cedillo, Ángel, Ortí, Guillermo, Jurado, Manuel
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/21115
Acceso en línea:https://hdl.handle.net/20.500.13003/21115
Access Level:acceso abierto
Palabra clave:Adolescent
Adult
Aged
Anthracyclines / adverse effects
Anthracyclines / therapeutic use
Female
Heart Diseases / etiology
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Incidence
Leukemia, Myeloid, Acute* / therapy
Male
Middle Aged
Transplantation, Homologous
Young Adult
Adolescente
Adulto
Anciano
Femenino
Humanos
Incidencia
Masculino
Persona de Mediana Edad
Trasplante Homólogo
Adulto Joven
Descripción
Sumario:This multicenter study sponsored by GETH-TC aimed to investigate the incidence and predictors of early (within the first 100 days) and late cardiac events (CE) (ECE and LCE) following allo-HCT in AML patients treated with anthracyclines, focusing on exploring the impact of PTCY on cardiac complications and the impact of CE on overall survival (OS) and non-relapse mortality (NRM). 1020 AML patients were included. PTCY was given to 450 (44.1%) adults. Overall, 94 (9.2) patients experienced CE and being arrythmias, pericardial complications, and heart failure the most prevalent ones. ECE occurred in 49 (4.8%) patients in a median of 13 days after allo-HCT, while LCE were diagnosed in 45 (4.4%) patients in a median of 3.6 years after transplant. Using PTCY increased the risk for ECE in multivariate analysis (HR 2.86, P=0.007), but did not not significantly affect the risk for LCE (HR 1.06, P=0.892). The impact of variables on outcomes revealed was investigated using multivariate regression analyses and revealed that the diagnosis of CE significantly decreased the likelihood of OS (HR 1.66, P=0.005) and increased the likelihood of NRM (HR 2.88, P<0.001). Furthermore, despite using PTCY increased the risk for ECE, its administration was found to be beneficial for OS (HR 0.71, P=0.026). The study suggests that while the incidence of CE was relatively low, it significantly impacted mortality. Standard doses of PTCY increased ECE risk but were associated with improved OS. Therefore, implementing protocols to prevent cardiac complications is recommended, considering the widespread adoption of PTCY in allo-HCT.

Similares en LA Referencia